Invex Therapeutics Ltd (ASX:IXC)
Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on the development of efficacious treatments for neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.
The Company was incorporated on 8 March 2019 with the goal of becoming a leading biopharmaceutical company focused on drug repurposing and neurology. The Company intends to achieve this through the research, development and potential commercialisation of more than 10 years of scientific discovery and technology development by Dr Alexandra J Sinclair and her group at The University of Birmingham, UK.
In what market does Invex operate?
Invex operates in the biopharmaceutical industry, seeking to develop efficacious treatments for neurological conditions resulting from raised intracranial pressure, such as IIH, traumatic brain injury or acute stroke. IIH is a condition of unknown cause, which results in raised pressure in the brain and can cause daily headaches and potentially permanent loss of sight.
For more information see the Invex Therapeutics Prospectus.